More mechanisms of resistance to anti-HER2 ADCs, this time with a focus on loss of target interaction!

Now online in Cancer Discovery @aacrjournals.bsky.social: Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding - by Wanyi Chen, @joshdragomd.bsky.social, @saratchandarlapaty.bsky.social, and colleagues doi.org/10.1158/2159... @mskcancercenter.bsky.social

Amazing to have our work featured on the cover of the latest issue of @natgenet.nature.com! The artwork, like the science, is a collaborative creation with everyone’s fingerprints 🎉 www.nature.com/articles/s41...

Published online today - work led by Yanyan Cai: Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers | Science Translational Medicine www.science.org/doi/10.1126/...

Published online today - work from our team led by Avantika Gupta, revealing how APOBEC3 mutagenesis promotes resistance to several targeted therapies in breast cancer. Check it out! urldefense.com/v3/__https:/...

So excited to share our latest work with @saratchandarlapaty.bsky.social, Antonio Marra, Andrea Gazzo @mskcancercenter.bsky.social out today in @natgenet.nature.com! We uncover the function and mechanism of APOBEC3-driven therapy resistance in breast cancer. 🧵 1/ www.nature.com/articles/s41...

@saratchandarlapaty.bsky.social expertly summarizing our work on how underlying genomic instability in breast cancer leads to therapy resistance leaving with key ideas on how we might target them! Come see me expand on the role of APOBEC3 mutagenesis in these processes tomorrow morning at #AACR25!

Congratulations to @reikudo.bsky.social for the beautiful work inspiring current+future studies! #SABCS24

So honored to have gotten the opportunity to present our work showing a prevalent role of APOBEC3 mutagenesis in driving therapy resistance in breast cancer at #SABCS24!

Great work from Dr Avantika Gupta in @saratchandarlapaty.bsky.social lab, linking APOBEC mutagenesis to facilitating therapy resistance in HR+ breast cancer. Lots of intriguing vulnerabilities to target that would be relevant in a lot of breast cancers! #SABCS24 www.biorxiv.org/content/10.1...

Fantastic presentation #SABCS by @avantikagupta.bsky.social on apobec3 in breast cancer. Demonstrating the role of this process in promoting therapy resistance.

Congratulations to @caiy0219.bsky.social for an excellent poster presentation today! 👏🏽 Also, so happy to be reunited with @reikudo.bsky.social to represent the translational team in @saratchandarlapaty.bsky.social’s lab at #SABCS2024!

@marie-will.bsky.social expertly setting up a major research focus and our latest work identifying a new resistance mechanism and a rational strategy to improve the efficacy of the HER2 #ADC T-DXd. Please check it out here: www.cell.com/cell-reports...